Quant ratings on Cathie Wood's top holdings: TSLA, CRSP, AMD, and TEM

Quant ratings on Cathie Wood's top holdings: TSLA, CRSP, AMD, and TEM
Cathie Wood’s Ark Invest leaned into volatility on Wednesday, buying shares of Tempus AI after a post-earnings pullback while trimming exposure to Pinterest following recent weakness in its outlook. Tempus AI shares fell more than 7% to $53.71 after the company reported a https://t.co/0IaJbvpWYn
Nancy Pelosi’s investment in Tempus AI is turning heads after the stock surged more than 200% this year. Earlier in 2025, Pelosi disclosed the purchase of 50 call options in Tempus AI, a healthcare-focused artificial intelligence company. The options, which expire in 2026 with a https://t.co/RQcfR1BVPT
Cathie Wood’s Ark Invest made a series of high-profile moves on Tuesday, reshuffling its portfolio across several sectors. The firm increased exposure to Advanced Micro Devices, Bullish, and Figma, while trimming its stake in Tempus AI. Ark’s Fintech Innovation ETF added nearly https://t.co/QvBQeiAvDv
Cathie Wood’s Ark Invest made several high-profile trades this week, shifting away from Tempus AI while increasing positions in Amazon, Figma, and crypto-focused Bullish. Ark sold more than 58,000 shares of Tempus AI across its ARK Genomic Revolution and ARK Innovation funds. https://t.co/DTZ8k1O1wA
Tempus AI announces $81.25M acquisition of Paige
7.48BUSD

Sehen Sie, welche Milliardäre diese Investition besitzen
Typ
Common Stock
Börse
NASDAQ
Währungscode
USD
Währungsname
US Dollar
Ländername
USA
Länder-ISO
US
ISIN
US88023B1035
CUSIP
-
Sektor
Healthcare
Branche
Health Information Services
Geschäftsjahresende
December
IPO-Datum
-
Aktualisiert am
-
PE-Verhältnis
-
PEG-Verhältnis
-
Buchwert
2.32
Dividende pro Aktie
-
Dividendenrendite
-
Gewinn je Aktie
-1.83
Wall Street-Zielpreis
67.23
EPS-Schätzung für das laufende Jahr
-0.36
EPS-Schätzung für das nächste Jahr
-0.08
EPS-Schätzung für das laufende Quartal
-0.2011
EPS-Schätzung für das nächste Quartal
-0.1483
Letztes Quartal
-
Umsatz TTM
1,364,167,936
Bruttogewinn TTM
864,734,976
EBITDA
-185,246,000
Gewinnmarge
-22.21%
Rendite auf Vermögen TTM
-9.07%
Rendite auf Eigenkapital TTM
-81.58%
Umsatz je Aktie TTM
7.735
Quartalsumsatzwachstum im Jahresvergleich
36.10%
Verwässertes EPS TTM
-1.83
Quartalsgewinnwachstum im Jahresvergleich
0.00%
Historisches PE
0.00
Erwartetes PE
0
Kurs-Umsatz-Verhältnis TTM
5.846
Kurs-Buchwert-Verhältnis MRQ
17.9669
Unternehmenswert / Umsatz
5
Unternehmenswert / EBITDA
0
0.97
5.32%203.19
0.55%21.11
0.26%112.23
0.00%59.68
-18.13%46.54
-5.87%5.92
-2.20%74.71
-0.65%49.87
-0.53%100.62
-0.39%